文献速递腹部外周血管介入CT

肝硬化患者经颈静脉肝内门体分流术后的肌少症

Sarcopenia in Patients with Cirrhosis after Transjugular Intrahepatic Portosystemic Shunt Placement.
PubMed 文献 · Radiology · 2022-03-15

本回顾性研究纳入2016年8月至2020年5月接受TIPS的224例肝硬化患者,于基线及术后2个月、5个月、1年行CT评估骨骼肌与脂肪量。肌少症患者术后骨骼肌指数与脂肪量增加,肌少症为死亡独立危险因素(HR 3.0),肌少症逆转者累积生存率更高(96.4% vs 82.1%,P=0.04)。

要点

  • TIPS术后肌少症患者骨骼肌指数增加,男性5个月达49.1 cm2/m2、女性达40.6 cm2/m2(P<.001)。
  • 肌少症是TIPS术后死亡的独立危险因素(HR 3.0,95%CI 1.2–7.8)。
  • 肌少症逆转者累积生存率96.4%,未逆转者82.1%(log-rank P=0.04)。

核心结论

  • 肌少症患者TIPS术后骨骼肌与脂肪量均增加;肌少症逆转可能降低死亡风险。

研究设计与样本

  • 回顾性研究,纳入2016年8月至2020年5月接受TIPS的224例肝硬化患者(男159例,女65例),于基线及术后2个月、5个月、1年行CT评估L3椎体水平骨骼肌与脂肪量。

诊断标准与关键数值

  • 肌少症定义为L3骨骼肌指数(SMI)男性<50 cm2/m2、女性<39 cm2/m2。

临床应用与阅片要点

  • 阅片时可于L3椎体水平测量骨骼肌指数评估肌少症,并关注TIPS术后骨骼肌与脂肪量的变化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Sarcopenia is frequently found in patients with cirrhosis and is associated with liver dysfunction, cirrhosis-related complications, and poorer quality of life. Purpose To evaluate changes in skeletal muscle and fat mass at CT and to evaluate the relationship of sarcopenia to mortality in patients with cirrhosis after transjugular intrahepatic portosystemic shunt (TIPS) placement. Materials and Methods Patients who underwent TIPS between August 2016 and May 2020 were included in this retrospective study. Skeletal muscle and fat mass were evaluated at CT at the L3 vertebra at baseline and at 2 months, 5 months, and 1 year after TIPS. Sarcopenia was defined as L3 skeletal muscle index (SMI) less than 50 cm2/m2 for men and less than 39 cm2/m2 for women. The primary end point was change in skeletal muscle and fat mass, and secondary end points included survival and the predictive factors for survival. Changes in skeletal muscle and fat mass over time were analyzed by generalized estimating equations. Results A total of 224 patients (159 men [113 with and 46 without sarcopenia] and 65 women [32 with and 33 without sarcopenia]) were included. In male patients with sarcopenia, the mean L3 SMI increased from 41.8 cm2/m2 (baseline) to 49.1 cm2/m2 (at 5-month follow-up; P < .001) and 49.6 cm2/m2 (at 1-year follow-up; P < .001) after TIPS. In female patients with sarcopenia, SMI increased from 33.7 cm2/m2 (at baseline) to 40.6 cm2/m2 (at 5-month follow-up; P < .001) and 42.0 cm2/m2 (at 1-year follow-up; P < .001) after TIPS. Sarcopenia (hazard ratio, 3.0; 95% CI: 1.2, 7.8) was identified as an independent risk factor for mortality after TIPS, and the patients who converted from sarcopenic to nonsarcopenic had higher cumulative survival rate than those who did not (96.4% vs 82.1%; log-rank P = .04). Conclusion In patients with sarcopenia, both skeletal muscle and fat mass increased after transjugular intrahepatic portosystemic shunt placement. The reversal of sarcopenia could reduce the risk of death. © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Lee in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Liu, Ma, Yang, et al. Sarcopenia in Patients with Cirrhosis after Transjugular Intrahepatic Portosystemic Shunt Placement. Radiology. 2022. PMID: 35289658. doi:10.1148/radiol.211172

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。